FINWIRES · TerminalLIVE
FINWIRES

Taiwan's Manufacturing Growth Accelerates in April as Costs Surge, S&P Global Says

By

-- Taiwan's manufacturing sector expanded at a faster pace in April as firms ramped up production and orders, while cost pressures intensified sharply, according to data released Monday by S&P Global.

The S&P Global Taiwan Manufacturing Purchasing Managers' Index rose to 55.3 in April from 53.3 in March, marking the strongest improvement in business conditions since December 2021.

Output grew at the second-fastest pace since June 2024, while new orders increased at the second-sharpest rate since July 2021, partly driven by stockpiling amid concerns over supply disruptions and rising prices.

New export orders also rose strongly, supported by demand from the U.S., Europe, mainland China, Japan, and Southeast Asia.

Firms stepped up purchasing activity at one of the fastest rates in nearly four-and-a-half years, while supplier delivery times lengthened at the fastest pace in just over four years.

Input costs rose at the steepest pace in nearly five years, prompting firms to lift selling prices at the quickest rate since late 2021.

Employment declined slightly, while business confidence eased to a three-month low, though firms remained optimistic about output growth, supported by expectations of stronger demand, particularly in AI-related sectors.

Related Articles

Research

Research Alert: CFRA Retains Buy Rating On Shares Of Stryker Corporation

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our target price to $360 from $438, 21.5x our 2027 EPS forecast, below SYK's 10-year historical average of 24.5x. We maintain our 2026 EPS forecast at $14.94 and our 2027 EPS estimate at $16.71. We think that Stryker's Q1 results were significantly impacted by the late-quarter cyber incident that caused global business disruptions, leading to a miss on both revenue and earnings estimates. Despite disruptions affecting manufacturing, shipments, and revenue recognition, management maintained the full-year 2026 guidance of 8% to 9.5% Y/Y organic sales growth and adjusted EPS in the range of $14.90 to $15.10, expecting to recover most lost sales, which we find encouraging. Key catalysts for the remainder of the year include the proposed acquisition of Amplitude Vascular Systems, which has the potential to expand Stryker's cardiovascular capabilities and the creation of a new Ortho Tech business, which could streamline innovation and customer experience, in our view.

$SYK
International

Philippine Manufacturing Activity Contracts as Orders Fall, Costs Rise, S&P Global Says

The Philippines' manufacturing sector slipped into contraction in April as new orders fell sharply and cost pressures intensified, according to data released Monday by S&P Global.The S&P Global Philippines Manufacturing Purchasing Managers' Index fell to 48.3 in April from 51.3 in March, marking the first contraction since November.New orders declined at the fastest pace since August 2021, while export demand weakened further, with firms citing trade route disruptions and halted shipments.Production stalled, and firms cut employment and purchasing activity, drawing down inventories to meet output needs.Input costs rose at the fastest pace since December 2022, driven by higher energy and shipping costs linked to the Middle East war, prompting the sharpest increase in selling prices in 41 months.Supplier delivery times lengthened, while business confidence improved to a 17-month high on expectations of stronger demand ahead.

$^PSEi
Research

Research Alert: CFRA Maintains Hold View On Shares Of Ametek, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Following AME's Q1 beat, we lift our 12-month target to $260 from $240, valuing shares at 29.5x our 2027 EPS outlook of $8.81 (up $0.20; 2026 EPS outlook lifted to $8.12 from $8.00), above AME's five-year historical multiple average given a strengthening earnings growth trajectory. Notably, AME experienced a Q1 acceleration in demand, highlighted by record orders of $2.2 billion, representing 22% organic growth and leading to a record backlog of $3.87 billion. This growth was broad-based, with sustained strength in Aerospace & Defense and a notable inflection in orders for the more cyclical Process and Power businesses. Profitability also was a positive, as core operating margins expanded by 160 basis points, driven by volume leverage in the Electromechanical Group (EMG). Overall, Q1 results were encouraging though shipment delays stemming from conflict in the Middle East was a modest headwind, indicating that spillover effects could become a bigger headache if instability in the region worsens.

$AME